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 The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis 
Screen (ECAS): Sensitivity in Differentiating between ALS and 
Alzheimer’s Disease in a Greek Population. 
Objectives: 1) Adapt the ECAS into Greek, validate it in ALS patients and compare 
with the ALS-CBS 2) Determine the sensitivity and specificity of ECAS in the 
differentiation between AD and non-demented ALS patients as compared with the 
ACE-III and mini-ACE.  
Methods: ALS patients (n=28) were recruited. and AD patients (n=26) matched in age, 
sex, and education with ALS patients (n=24). The normative data was derived from a 
random sample of controls (n=52). Bayes correlation analysis was conducted to 
examine convergent validity. Bayes t-test was performed to assess between groups’ 
differences. Receiver operating characteristics (ROC) curve analyses and area under the 
curve (AUC) were implemented to appraise the sensitivity and specificity in the 
differentiation between AD and non-demented ALS patients.  
Results: The ECAS and its sub-scores in addition to the behaviour interview 
demonstrated robust correlations with the ALS-CBS. Impairment in language and 
verbal fluency were the most prominent deficits in the ALS patients. The most 
frequently reported change was apathy. The ROC analysis demonstrated that the 
ECAS-ALS Non-Specific score (comprising memory and visuospatial domains) is the 
most sensitive and specific in differentiating AD from ALS patients. The other 
measures expressed high sensitivity, yet a poor specificity.  
Conclusions: The ECAS is a multi-purpose screening tool. The ECAS-ALS Specific 
appraises the whole spectrum of the highly prevalent cognitive impairments in ALS. 
The ECAS-ALS Non-Specific (memory and visuospatial) is a sensitive score to detect 
AD related deficits and is able to differentiate AD from non-demented ALS patients 
better than the ACE-III and mini-ACE 
Keywords: Greek; ECAS; ALS; Alzheimer’s Disease; ACE-III 
 
 
 
 Introduction 
Cognitive impairment in the ALS can be found in 15–60% of patients [1, 2], whilst almost 
10% present with frontotemporal dementia (FTD), with the behavioural variant (bvFTD) 
being most prevalent [1, 3]. The most ubiquitous deficits in ALS are related to executive 
dysfunction and verbal fluency [4]. However, evidence of language deficit and compromised 
social cognition have been revealed [5–8]. Behavioural changes include apathy and 
disinhibition, similar to those in bvFTD [8]. Accordingly, diagnostic criteria have been 
proposed to differentiate between ALS with cognitive (ALSci) and/or behavioural changes 
(ALSbi) and ALS with FTD incorporating the recent findings of a more heterogeneous 
cognitive profile [9]. 
The ALS Cognitive Behavioural Screen (ALS-CBS) is the sole screening tool 
detecting cognitive impairment in ALS that has been translated into Greek [10]. It is a short 
bedside screen (administration time ≤ 10 mins) that assesses frontal lobe-mediated cognitive 
and behavioural changes [10, 11]. Studies in ALS have demonstrated that 40–50% of patients 
show impairment on conventional tests of executive functions [2, 5, 12]. The ALS-CBS 
includes a section that assesses executive functions and appears to be an appropriate tool to 
assess ALS patients [10, 11]. However, it has not been designed to assess the more recently 
recognized heterogeneous cognitive impairments in ALS, namely in language and social 
cognition [9]. 
Alternatively, the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) has 
been developed as a more comprehensive brief assessment [13, 14]. It has been adapted for 
Italian [15], German [16], Chinese [17], Dutch [18], and Spanish [19] populations. The 
ECAS is a brief screening tool (administration time approximately 20 mins) that is adjustable 
for patients with various motor impairments. It comprises a comprehensive assessment of a 
spectrum of cognitive and behavioural abnormalities in ALS [9, 13–19]. Furthermore, it has 
been validated in detecting the milder focal impairments in ALS (14, 20). The ECAS 
comprises an ALS-specific score (executive function, social cognition, verbal fluency, and 
language), an ALS-non-specific score (memory and visuospatial functions), and a carer’s 
interview to detect the behavioural and psychotic changes typical in FTD [9, 13–19]. 
Importantly, the ECAS assesses the recently recognized impairments in inhibitory control 
[10], social cognition [21], and language, which have been reported as highly prevalent in 
ALS [6, 7]. In particular, it assesses object naming [22, 23], utility and comprehension of 
 verbs [24], and spelling [25]. Furthermore, the ECAS has been designed to identify the 
changes that are not typical of ALS but are characteristic of other disorders, particularly 
Alzheimer’s disease (AD) [13]. However, the profile of impairment on the ECAS in AD is 
yet to be demonstrated. 
This study aimed to 1) Adapt the ECAS into Greek, validate it in ALS patients and 
compare it with the ALS-CBS. It should be noted that the ECAS has demonstrated good 
convergent validity with the ALS-CBS in a Spanish ALS population [19]. 2) Determine the 
sensitivity and specificity of ECAS in the differentiation of AD from non-demented ALS 
patients as compared to the ACE-III and mini-ACE.  The relationship between the ACE-III 
and the ECAS has been previously examined in a healthy population, and the ECAS was 
found to be less affected by IQ and ceiling effects [26]. 
Methods and Materials 
Participants  
All the participants and/or their carers signed an informed consent form in compliance with the 
revised Declaration of Helsinki, 1987. The present study was approved by the Psychology 
Research Ethics Committee of the University of Edinburgh and the Aeginition Hospital Ethics 
Committee. All participants had to be Greek native speakers and be free from the following: 
(1) psychiatric disorders, (2) psychoactive drugs, antidepressants, and anticonvulsants, (3) 
neurological conditions affecting cognition (other than ALS and AD for the respective 
patients), (4) learning disabilities, (5) alcoholism and drug abuse, and (6) uncontrolled systemic 
disease. 
ALS Patients 
The ALS patients (n = 28) were recruited in the Neurological Clinic (inpatients) and ALS Clinic 
(outpatients) of Aeginition Hospital, Athens, Greece. The recruitment was conducted in 
accordance with the general inclusion criteria and the following inclusion criteria specific to 
ALS: (1) a diagnosis of definite, probable, probable and laboratory-supported, or possible ALS 
based on the revised El Escorial criteria [27], (2) no clinical diagnosis of frontotemporal 
dementia as defined by the Neary et al. criteria (FTD) [28], and (3) absence of significant 
respiratory failure (forced vital capacity < 70%). A neuropsychologist and/or psychiatrist 
interviewed the patients and administered the ALS Depression Inventory (ADI-12) (cut-off > 
or = 23) [30] to discount patients with major depressive symptomatology. The patients’ motor 
 ability was evaluated using the revised Amyotrophic Lateral Sclerosis Functional Rating Scale 
(ALSFRS-R) [29]. The disease duration was calculated in months, from the onset of first 
symptoms to the testing date. Lastly, 28 caregivers (close relatives of the patients) of the ALS 
were interviewed to assess behavioural changes in ALS. 
AD Patients  
AD patients (n = 26) of the Maroussi Alzheimer Clinic, Athens, Greece were recruited to match 
a subgroup of ALS patients (n = 24) in age, sex, and education. The recruitment was conducted 
in accordance with the general inclusion criteria and the following inclusion criteria specific to 
AD: (1) a diagnosis of AD according to the National Institute of Neurological and 
Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) [31], (2) an absence of a mixed concomitant dementia processes (e.g., AD 
and vascular dementia). A neuropsychologist and/or psychiatrist interviewed the patients and 
administered the Hospital Anxiety and Depression Screen (HADS) [32] (cut-off > or = 8) to 
discount the patients who presented major depression or anxiety symptoms that may 
compromise their performance. The duration of the disease was calculated in years, from the 
onset of the first symptoms to the testing date. Lastly, 26 caregivers (close relatives of the 
patients) of the AD patients were interviewed to assess behavioural changes in AD. 
Healthy Subjects 
108 healthy participants were recruited who were either (1) members of Athens Association of 
Alzheimer’s Disease and Related Disorders, Athens, Greece; (2) or members of the ALS 
HELLAS patients’ association; (3) or volunteers who responded to the calls of the 
aforementioned associations. For the recruitment we implemented the above-mentioned 
general inclusion criteria. 56 were recruited to provide the data for the verbal fluency index 
(VFI) conversion tables of ECAS. A separate group of 52 healthy participants were recruited 
to form the ECAS normative data. These groups were distinct from each other with no overlap.  
Procedures  
Translation-Adaptation 
The adaptation of ECAS was conducted in accordance with the guidelines by Abrahams et 
al.,2014 (https://ecas.psy.ed.ac.uk/ )[13]. The ECAS comprises a written or spoken verbal 
fluency task of the letters ‘S’ and ‘T’. The letters ‘Σ’ (Sigma) and ‘Π’ (Pi) were opted for the 
Greek version. The letter ‘Σ’ in Greek resembles the difficulty of ‘S’ in English [33], while ‘Π’ 
 is similar to the difficulty level of ‘T’ in English. However, the rule of producing words using 
only 4 letters was modified to 5 letters due to the scarcity of 4-letter words in Greek. The 
spoken and written versions of both letters were administered separately to a different sample 
of healthy controls to produce the VFI conversion tables of ECAS (see Box 1 in Supplementary 
Material). The calculations were made as per the ECAS translation instructions [13]. 
The adaptation of ACE-III and M-ACE in Greek required minor modifications, since 
most of the tasks remained the same as in ACE-R. The sole significant adjustment was in the 
task of proverb repetition. In terms of pronunciation, the first item should be a low-difficulty 
proverb, i.e., ‘All that glitters is not gold’ and the second item should be a medium- to hard-
difficulty, i.e., ‘A stitch in time saves nine’. The proverbs of the Greek version are culturally 
adjusted and correspondent to this difficulty measure, i.e., ‘All that glitters is not gold’ and 
‘Better donkey-tying than donkey-seeking’. 
Administration of Screens - Spoken and Verbal Versions of ECAS 
The 52 healthy participants for the normative data were allotted to two groups matched in age, 
sex, and education. The spoken version of the ECAS was administered to the first group, while 
the written version of the ECAS was administered to the second. The rest of the screens were 
administered to both groups. 
Statistical Analyses 
Thresholds of p < 0.05 (two-tailed) and BF10 ≥ 10 were used for statistical inference. The 
demographic and cognitive data were analysed and compared. Between-group comparisons 
were made via Bayesian independent sample t-tests. Bayesian Pearson Correlation Analysis 
was used to assess the associations between screening tools. Receiver operating characteristics 
(ROC) curve analyses and area under the curve (AUC) were implemented to appraise 
sensitivity and specificity in the differentiation between AD and non-demented ALS patients. 
The statistical analyses were executed using the IBM Statistical Package for the Social Sciences 
(SPSS) 24.0. (Scale, ROC, and AUC analyses) [34], and JASP version 0.8.1.2 (Bayesian 
Pearson’s Correlation analyses, Bayesian t-tests) [35]. 
Inter-Rater Reliability & Internal Consistency  
The inter-rater reliability between the assessors and the independent interviewer was appraised 
using the Intraclass Correlation Coefficient (ICC), which displays the outcomes from ‘no 
match’ = 0 to ‘seamless match’ = 1 [36] (see Box 2 in Supplementary Material). The internal 
 consistency of the Greek versions of ECAS and ACE-III was determined by the calculation of 
Cronbach’s alpha coefficient. A Cronbach’s alpha coefficient of 0.70 or greater was considered 
substantial [37]. 
Results  
The descriptive statistics of the normative sample are displayed in Supplementary Material 
Table 1, together with the suggested cut-offs for abnormality. No significant difference was 
detected between the written and spoken versions of the ECAS. 
Inter-Rater Reliability & Internal Consistency 
The inter-rater reliability analysis displayed ICC = 0.88 for the ECAS, which postulates an 
almost seamless agreement between the assessors and substantial suitability for clinical 
implementation [36]. The scale analyses demonstrated an excellent internal consistency with 
Cronbach’s alpha = 0.84 [37]. 
Correlations with Education & Age 
Educational level correlated with the total score of ECAS but not with the ECAS-ALS Specific, 
ECAS-ALS Non-Specific, ACE-III, M-ACE, and ALS-CBS (see Table 2 in Supplementary 
Material). Further, the age of participants did not correlate with any of the above scores. 
Convergent Validity of ECAS against ALS-CBS 
The ECAS and its sub-scores demonstrated a robust correlation with the ALS-CBS (see Table 
3 in Supplementary Material). The ECAS Behavioural score also correlated with the ALS-CBS 
behavioural score. The subsequent Bayesian analysis of the correlations confirmed the 
convergent validity of the screens. 
Cognitive and Behavioural Changes in ALS as Assessed by the ECAS 
Impairment in language and verbal fluency were the most prominent deficits in ALS patients, 
followed by executive functions (see Figure 1). 64% of the ALS group presented with a 
behavioural change. The most frequent behavioural change was apathy, followed by loss of 
sympathy and perseverative behaviour (see Figure 2). Changes in eating behaviour were less 
commonly found among this population. 
 
 
 Differentiation between ALS and AD Patients 
The researchers examined which screen or sub-score would be most effective in 
discriminating between AD and ALS patients. The ROC analysis demonstrated the ECAS-
ALS Non-Specific score to be the most sensitive and specific in differentiating AD between 
ALS patients (see Figure 3). The other measures expressed high sensitivity but poor 
specificity. The sensitivity and specificity of each screen are displayed in Table 1. The ALS 
group performed significantly better than the AD group in all the measures (see Table 2). 
However, the former showed greater behavioural changes than the latter. 
In ALS patients, the Bayes correlation pairs analysis revealed an absence of substantial 
evidence (BF10 ≥ 3) for a correlation between either the total scores or the sub-scores of the 
tests and either the disease duration or ALSFRSR. The ECAS Behavioural and ALSFRS-R 
alone correlated significantly as r (26) = -44, p<.05, BF10 = 3.15.  
Discussion 
The ECAS in Greek Population 
The present study validates the Greek ECAS in ALS patients and demonstrates good 
convergent validity with the already adapted Greek version of ALS-CBS for both cognitive 
and behavioural components. The ECAS also exhibited substantial internal consistency, 
allowing implementation in clinical and research settings [36], and excellent inter-rater 
reliability, permitting its extensive utilisation by various clinical practitioners [37]. Therefore, 
the Greek ECAS can be considered a valid and effective tool for clinical and research purposes. 
Behavioural and Cognitive Changes in ALS      
In the present study, 50% of the subjects were impaired on the ECAS Total score and 46% on 
the ECAS-ALS Specific score, which is in accordance with other studies [5, 12, 14–16]. The 
most prominent cognitive impairments were found in language (36%), verbal fluency (36%), 
and executive functions (32%), which aligns with the previous studies in ALS patients [5, 13–
20, 38]. Moreover, the comorbidity of impairments was detected only in a small percentage of 
the ALS patients in language and verbal fluency (14%), language and executive functions 
(14%), verbal fluency and executive functions (14%), and language, executive function, and 
verbal fluency (11%). 
 The prevalence of executive function and verbal fluency in addition to language 
impairment in the current study is in accordance with the English, Italian, and German 
validation studies of ECAS [12, 13, 15] and with an extended systematic review of 44 
neuropsychological studies with 1130 ALS patients, where language dysfunction appeared to 
be the most prevalent cognitive impairment [38]. These findings are aligned with the recently 
revised diagnostic criteria of Strong et al., 2017 for cognitive and behavioural impairment in 
ALS [9]. 
The most frequently reported behavioural changes were apathy (54%), loss of sympathy 
(29%), and compulsive behaviour (22%). The first two changes have been considered as highly 
prevalent behaviour changes in previous studies [12–20]. The present study and the Italian 
validation study of the ECAS highlighted comparably high percentages of apathetic behaviour 
(54% and 45%, respectively) [15]. Moreover, an increased ECAS–Behavioural score was 
associated with poorer physical function, as assessed by the ALSFRS-R. These findings are, 
hence, in line with Lillo et al. (2012) and Crockford et al. (2018). It can be postulated that the 
behavioural changes seem to become prevalent in ALS as the neurodegeneration progresses 
and the functionality rate deteriorates [12, 39]. Notably, in this sample, neither the depression 
index, nor the ECAS-Behavioural score were related to any cognitive measure. 
Differentiation of ALS cognitive and behavioural profile from AD  
ALS patients presented with more behavioural changes than AD patients. However, these 
results should be interpreted cautiously. Behavioural changes in AD are more likely to be 
presented in the later stages of the disease, when cognitive decline is marked [40]. Our sample 
included early-to-mid-stage AD patients who presented mild-to-moderate cognitive decline. 
Therefore, we recommend caution in using the ECAS Behavioural screen alone to differentiate 
between ALS and AD patients; it should be used in conjunction with the cognitive performance 
profile. 
In contrast, ECAS-ALS Non-Specific was the most sensitive and specific score when 
differentiating between AD and non-demented ALS patients. ACE-III and M-ACE were 
sensitive, but not specific, in differentiating between the diseases. The superior performance of 
the ECAS ALS Non-Specific could be attributed to its adjustments to motor disability. 
However, ACE-III and M-ACE do not accommodate for physical decline. Hence, the ALS 
patients’ deficits were most likely exaggerated by these tests. Furthermore, the ECAS ALS 
Non-Specific score assesses memory and visuospatial abilities that are recognized to be 
 impaired disproportionately in AD. The sensitivity of the ECAS ALS Non-Specific score also 
permits the identification of AD in ALS patients, which is of great clinical benefit. 
Utility of the Screens   
The ALS-CBS is adjusted to possible motor impairments and comprises a behavioural 
assessment. The ALS-CBS efficiently detects frontal-mediated cognitive impairments and 
behavioural changes and requires a short administration time. However, it does not use a VFI 
to convert the score in the verbal fluency task, and it does not include a language task even 
though language impairment is highly prevalent among ALS patients [5, 9, 13–16, 38]. 
In contrast, the ECAS with two distinct sub-scores and the behavioural interview have 
displayed the characteristics of an exceptional multi-purpose screening tool. The behavioural 
outcomes may accompany the cognitive profile of the patient and inform about the probable 
caregiver’s burden. The ECAS-ALS Specific appraises the whole spectrum of highly prevalent 
cognitive impairments in ALS patients [9, 13–20]. The ECAS-ALS Non-Specific is a sensitive 
screening tool used to detect AD-related deficits and to differentiate AD patients from non-
demented ALS patients. In poly-pathological clinical settings, where possible motor disabilities 
are prevalent amongst patients, the ECAS is an indispensable screening tool. However, in 
patients with severe motor dysfunction in upper limbs and impaired speech, tests that use brain 
machine interface [41] or eye-tracking technology [42] may be more appropriate [41, 42]. 
The study is limited by the small size of the sample. Also, in accordance with previous 
studies, the educational level was associated with both, the ECAS and the ACE-III [11, 15–
17]. However, the ACE-III appeared to be significantly more dependent on the IQ and with 
greater ceiling effects than the ECAS, which may be an important advantage of the ECAS for 
use among clinical populations [26]. In the current study, cut-offs adjusted to the educational 
level are not specified. The healthy participants in this study belonged to an older age range 
(63% > 60) and had a low educational level (62% < 13 years). The abnormality cut-offs 
presented here are, therefore, conservative. The absence of adjusted cut-off scores may have 
influenced the estimates of abnormality rates. Furthermore, the validation of the ECAS was 
against ALS-CBS, which does not assess the whole spectrum of cognitive changes in ALS 
patients. Thus, in line with previous studies, validation against a comprehensive 
neuropsychological battery [14, 20] as well as the acquisition of larger normative data to 
calculate adjusted cut-offs to the educational level are strongly recommended [15, 18, 43, 44]. 
In this study, only ALS patients without dementia were recruited, and their genetic status was 
 unknown. Future studies can investigate the ALS-FTD profile and genetic subtypes. In 
conclusion, this study demonstrates a highly effective tool for evaluating the range of cognitive 
and behaviour changes in the Greek population that can assist in managing patient care and 
alleviating the caregivers’ burden. 
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                                  Supplementary Material – ALS  
Box 1 – Verbal Fluency Index Calculation 
Box 2 – Inter-Rater Reliability 
Table 1 – Normative Data 
 N Range Minimum Maximum Mean (SD) Cut-off 
Age 
 
52 38 48 86 67.25 (9.69)  
Education 
 
52 14 6 20 12.63 (3.22)  
Sex 
 
26F/26M      
ALS-CBS 
 
52 5 14 19 16.37 (1.22) ≤ 13/30 
ECAS Total Score 52 36 93 129 109.73 (8.35) ≤ 93/136 
ECAS-ALS Specific 52 25 68 93 80.81(6.33) ≤ 68/100 
ECAS-ALS Non-Specific 52 12 24 36 28.92 (2.88) ≤ 23/36 
ACE-R 52 14 85 99 91.94 (3.61) ≤ 82/100 
MMSE 52 8 22 30 27.65 (1.91) ≤ 22/30 
ACE-III 52 15 84 99 92.04 (3.81) ≤ 83/100 
M-ACE 52 8 22 30 26.96 (2.12) ≤ 23/30 
SD = Standard Deviation; Cut-offs indicate 2 SDs distance below the mean, they are presented out of the maximum score.  
15 males and 13 females, age 57.07 years old (11.28), education 12.6 years (2.87), were tested in the 
spoken task of both letters (Π and Σ) to produce two discrete tables of the spoken Σ and Π.  28 healthy 
participants, 12 males and 16 females, age 56.97(9.15), education 13.73(2.84), were examined in the 
written task of both letters to develop the distinct tables of written Σ and Π.  
The 4 assessors and the independent reviewer were equally trained in the administration and scoring of 
ECAS based on the relevant guidelines (https://ecas.psy.ed.ac.uk/). The 4 assessors administered the 
screens to healthy participants (N=52), ALS patients (N=28), and AD patients (N=26). The responses 
of the examinees were also recorded (typed) in a distinct sheet, which were solely accompanied with an 
id-number to maintain traceability and anonymity. The independent reviewer hence was blinded to the 
identity of both the examiner and the examinee. The independent reviewer evaluated the responses of 
the participants from all populations (N = 106). We thus formed two groups of scores i.e. (1) by the 4 
assessors; (2) by the independent reviewer. The inter-rater reliability was calculated between the scores 
(ECAS Total Score, ECAS ALS-Specific, ECA ALS-Non-Specific) provided by the 4 assessors (1), 
and the independent reviewer (2). The inter-rater reliability analysis indicated an excellent ICC for all 
the scores i.e. ECAS Total Score (ICC = .88), ECAS ALS-Specific (ICC = .86), and ECA ALS-Non-
Specific (ICC = .92). However, regarding the suitability of the ECAS for clinical implementation, 
solely the ICC of ECAS-Total Score (ICC = .88) should be considered. 
 
Table 2 – Bayesian Pearson’s Correlations with Education & Age 
BF= Bayes Factor; * BF₁₀ > 10, ** BF₁₀ > 30, *** BF₁₀ > 100 
 
Table 3 – Convergent Validity in ALS: Bayesian Pearson’s Correlations 
BF= Bayes Factor; * BF₁₀ > 10, ** BF₁₀ > 30, *** BF₁₀ > 100 
 
Correlational Pairs Pearson’s r p-value BF₁₀ 
Education & ECAS Total Score 
  0.401 * p<.01 11.647 
 
Education & ECAS ALS-Specific 
0.356 p<.01 4.517 
 
Education & ECAS ALS Non-Specific 
0.379 p<.01 7.213 
 
Education & ALS-CBS 
0.204 0.15 0.481  
Education & ACE-III 0.284 p<.05 1.307  
Education & M-ACE 0.207 0.14 0.497  
Education & ACE-R 0.202 0.15 0.472  
Education & MMSE 0.126 0.38 0.254  
Age & ECAS Total Score -0.163 0.25 0.331  
Age & ECAS ALS-Specific -0.213 0.13 0.528  
Age & ECAS ALS Non-Specific -0.005 0.97 0.173  
Age & ALS-CBS -0.035 0.80 0.178  
Age & ACE-III 0.104 0.46 0.225  
Age & M-ACE 0.077 0.59 0.199  
Age & ACE-R 0.003 0.98 0.173  
Age & MMSE -0.198 0.16 0.452  
Correlational Pairs Pearson’s r p-value BF₁₀ 
ALS-CBS & ECAS Total Score 
 0.818 *** 
p<.001 
2.271e +22  
ALS-CBS & ECAS ALS-Specific 
 0.821 *** 
p<.001 
8.078e +22  
ALS-CBS & ECAS ALS Non-Specific 
 0.490 *** 
p<.001 
186.2  
ALS-CBS & ACE-III 
 0.775 *** 
p<.001 
2.615e +9  
ALS-CBS & M-ACE 
 0.725 *** 
p<.001 
3.118e +7  
ALS-CBS Behavioural & ECAS Behavioural -0.750 *** 
p<.001 
2356  
Table 1 – Sensitivity and Specificity in differentiation between AD and ALS patients 
Screen     AUC  Cut-Off      Sensitivity           Specificity 
ECAS Total Score      85%      93          92%               55% 
ECAS-ALS Specific      78%      68          81%               55% 
ECAS-ALS Non-Specific     99%        23          96%               91% 
ACE-III Total Score      91%      83          89%               76% 
M-ACE Total Score      87%      23          97%               71% 
The finest tool to discriminate between AD and ALS is presented in bold.  
 
Table 2 – Comparison Between ALS & AD Patients: Descriptive Statistics  
 ALS – Mean (SD) AD - Mean (SD) p-value BF₁₀ 
N = 50 
 
24 26   
Sex 
 
14M / 10F 14M / 12F   
Age 
 
68.54 (7.05) 67.19 (4.06) 0.33 0.303 
Education 
 
11.13 (3.22) 11.12 (3.18) 0.26 0.283 
ECAS Total Score 
 
93.04 (13.27) 69.81 (17.93) ***p<.001 3396.250 
ECAS-ALS Specific 
 
65.63 (11.30) 54.19 (14.51) *p<.001 11.616 
ECAS-ALS Non-Specific 
 
27.17 (3.45) 15.62 (5.86) ***p<.001 1.163e +8 
ECAS-Behavioural 
 
1.42 (1.47) 0.38 (0.64) *p<.001 17.258 
ACE-III 
 
85.63 (9.50) 62.31 (18.01) ***p<.001 15257.238 
M-ACE 
 
24.17 (4.80) 15.08 (6.72) ***p<.001 8387.337 
SD = Standard Deviation; BF= Bayes Factor; * BF₁₀ > 10, ** BF₁₀ > 30, *** BF₁₀ > 100 
 
Figure 1 – Percentages of Abnormal Performance in ALS Patients 
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Figure 2 – Percentages of Behavioural Changes in ALS Patients 
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Figure 3 - ROC Curves: Differentiation between AD and ALS patients 
 
